Immunotherapy combo tested for rare kidney cancer, but trial stopped early
NCT ID NCT03274258
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 people with a rare and aggressive kidney cancer called renal medullary carcinoma. The goal was to see if the drugs could shrink tumors or slow cancer growth. However, the study was terminated early, so the results are limited and it is unclear how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to
If it works, this could point toward a treatment option for a rare and aggressive kidney cancer.
What could go wrong
The trial was terminated early with only 10 participants, so results are very limited. Immunotherapy can cause serious side effects like organ inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States